AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Consumption tuberculosis12/13/2023 ![]() Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. 2010 Oct 1.īellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Inhaled Corticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Mycobacterial factors relevant for transmission of tuberculosis. Verhagen LM, van den Hof S, van Deutekom H, et al. Risk of tuberculosis infection and disease associated with work in health care settings. Delayed recognition and infection control for tuberculosis patients in the emergency department. Implementation of an emergency department triage procedure for the detection and isolation of patients with active pulmonary tuberculosis. Trends in Tuberculosis – United States, 2011. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance WHO. Antituberculosis drug resistance in the world. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. 196 Suppl 1:S86-107.īurman WJ, Goldberg S, Johnson JL, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. Wells CD, Cegielski JP, Nelson LJ, et al. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Accessed: November 7, 2012.Īsensio JA, Arbues A, Perez E, Gicquel B, Martin C. Centers for Disease Control and Prevention. 67 (25):723-726.Įxtensively Drug-Resistant Tuberculosis (XDR TB). ![]() Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection. 365(23):2155-66.īorisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. Sterling TR, Villarino ME, Borisov AS, et al. Safety and Side Effects of Rifampin versus Isoniazid in Children. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. Menzies D, Adjobimey M, Ruslami R, et al. Targeted tuberculin testing and treatment of latent tuberculosis infection. WHO consolidated guidelines on drug-resistant tuberculosis treatment. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Treatment of Drug-Resistant Tuberculosis. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. When to start antiretroviral therapy in HIV-associated tuberculosis. Timing of initiation of antiretroviral drugs during tuberculosis therapy. Ībdool Karim SS, Naidoo K, Grobler A, et al. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. 181(7):743-51.Ĭenters for Disease Control and Prevention. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Swaminathan S, Narendran G, Venkatesan P, et al.
0 Comments
Read More
Leave a Reply. |